APA (7th ed.) Citation

Suder, A., Ang, J., Kyle, F., Harris, D., Rudman, S., Kristeleit, R., . . . Spicer, J. (2015). A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. European Journal of Cancer, 51(16), 2275. https://doi.org/10.1016/j.ejca.2015.07.041

Chicago Style (17th ed.) Citation

Suder, A., et al. "A Phase I Study of Daily Afatinib, an Irreversible ErbB Family Blocker, in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours." European Journal of Cancer 51, no. 16 (2015): 2275. https://doi.org/10.1016/j.ejca.2015.07.041.

MLA (9th ed.) Citation

Suder, A., et al. "A Phase I Study of Daily Afatinib, an Irreversible ErbB Family Blocker, in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours." European Journal of Cancer, vol. 51, no. 16, 2015, p. 2275, https://doi.org/10.1016/j.ejca.2015.07.041.